WANY
SRPT icon

Wealthspire Advisors (New York)’s Sarepta Therapeutics SRPT Stock Holding History

Wealthspire Advisors (New York)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-593
Closed -$11.4K – 2643
2025
Q3 		$11.4K Buy
+593
New +$10.6K ﹤0.01% 1953
2020
Q2 		– Sell
-2,557
Closed -$250K – 494
2020
Q1 		$250K Buy
+2,557
New +$292K 0.01% 432

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Wealthspire Advisors (New York)'s SRPT Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 593 shares — an estimated $11.4K sold.

Wealthspire Advisors (New York) first reported a position in SRPT in Q1 2020 and held it in 2 quarters. The position peaked at $250K in Q1 2020. 346 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 593 Sarepta Therapeutics shares in Q4 2025, an estimated $11.4K.
  • Wealthspire Advisors (New York) first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 2 quarters.
  • Wealthspire Advisors (New York)'s Sarepta Therapeutics position peaked at $250K in Q1 2020.
  • 346 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.